Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare, progressive and life-threatening neurodegenerative disorder that affects approximately 1,000 people in Europe. The European Commission is expected to issue its final decision on the Marketing Authorization Application within 67 days.

Zevra will continue to support eligible patients currently receiving arimoclomol through its global Expanded Access Program (EAP), subject to applicable regulatory requirements and in coordination with national authorities. The Company remains focused on helping ensure continuity of treatment for patients currently benefiting from arimoclomol through the program.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.